Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Three months ended December 31, 2014 (first quarter of fiscal 2015; unaudited). The company changed its fiscal year-end to September 30 following its September 2014 reverse acquisition. It files Exchange Act reports voluntarily.
Business context
Citius develops drug formulations and delivery technologies. Its approved product, Suprenza, is licensed to Prenzamax for U.S. commercialization; the company reported no revenue because it had not earned royalties, profit-share payments, or development-cost reimbursements under its agreements. The company remained dependent on outside financing to fund operations.
Financial performance and position
| Metric | Three months ended Dec. 31, 2014 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $477,123 | $437,397 |
| General and administrative expense | $293,018 | $61,796 |
| Stock-based compensation | $108,764 | $0 |
| Total operating expenses / operating loss | $878,905 | $499,193 |
| Net loss | $823,708 | $534,414 |
| Basic and diluted loss per share | $0.03 | $0.03 |
| Net cash used in operating activities | $734,823 | $521,882 |
No operating margin is meaningful because the company reported no revenue. R&D increased $39,726, primarily from development of a hemorrhoid-treatment product and costs related to Suprenza. G&A rose $231,222, reflecting new CEO compensation, consulting, insurance, and professional fees. Net loss increased $289,294.
At December 31, 2014, cash and cash equivalents were $817,237, down from $1,552,060 at September 30. Total assets were $822,638; current liabilities were $1,646,184; working capital deficit was $828,947; and stockholders’ deficit was $823,546. The balance sheet showed no promissory-note balance after conversion, and a $1,390,454 derivative warrant liability. The filing reports no interest or income taxes paid during the quarter.
Material changes, financing, and unusual items
- On December 31, holders converted $600,000 of promissory notes plus $33,333 accrued interest into 1,055,554 common shares at $0.60 per share. This noncash transaction eliminated the notes from current liabilities.
- A $60,489 gain from revaluing derivative warrants reduced the reported net loss. The liability’s fair value is based on a Level 3 valuation model and management assumptions.
- Stock-based compensation of $108,764 was recorded for CEO options. At quarter-end, 3.3 million options were outstanding and 5.76 million warrants were reserved for issuance.
- Cash used in operations was $734,823; the company reported no financing cash inflows in the quarter.
Outlook, risks, and controls
Management expected available funds to support operations for the next nine months and planned to seek additional equity capital. It cautioned that financing may not be available, or may not be available on acceptable terms or in time. The filing states that limited capital, operating losses, no company revenue, a working capital deficit, and negative operating cash flow raise substantial doubt about the company’s ability to continue as a going concern.
Key risks include raising capital, clinical-trial success, product commercial viability and acceptance, regulatory approvals, and reliance on key personnel, suppliers, and strategic partners. The company reported no legal proceedings and no change in risk factors from its most recent Form 10-K. Disclosure controls were deemed ineffective as of September 30, 2014, with material weaknesses including no independent board or audit committee, undocumented procedures, reliance on consultants for financial reporting, and inadequate segregation of duties. No material control changes were reported during the quarter.
Important facts for investors to verify
- Whether the company raised sufficient additional capital after quarter-end and how long its cash runway ultimately proved to be.
- Whether Suprenza generated payments to Citius under the Prenzamax and Alpex agreements, and whether the hemorrhoid-treatment program advanced.
- The terms and potential dilution from outstanding warrants, options, and future equity financing; also verify the valuation assumptions behind the warrant liability.
- Whether the identified internal-control weaknesses were remediated and whether subsequent filings continued to identify going-concern uncertainty.